Repligen (RGEN) Stock Price, News & Analysis

Company Overview

Repligen Corporation (NASDAQ: RGEN) is a life sciences company specializing in the development and manufacture of bioprocessing technologies for the production of biologic drugs. Founded in 1981 and headquartered in Waltham, Massachusetts, the company provides a suite of consumable products and systems designed to streamline upstream and downstream processes in biomanufacturing. Its offerings include chromatography resins, membrane chromatography devices, single-use filters and sensors, as well as protein A affinity resins utilized in monoclonal antibody purification.

In addition to consumables, Repligen delivers integrated bioprocess systems such as perfusion technologies and cell culture platforms that support continuous processing workflows. The company’s OPUS chromatography columns are engineered for rapid method development and scale-up, while its RUDI perfusion system enables intensified cell culture to increase product yields. These tools are complemented by proprietary single-use assemblies that enhance process efficiency and reduce the risk of cross-contamination.

Repligen serves a global customer base of biopharmaceutical developers and contract manufacturing organizations. With operational facilities and sales offices across North America, Europe, and Asia, the company supports research and commercial manufacturing activities in key biopharma hubs. Its products are widely adopted by leading pharmaceutical companies for applications in antibody, vaccine, gene therapy and cell therapy production.

Under the leadership of President and CEO Dr. Matthew Denton, Repligen has expanded its portfolio through both internal innovation and strategic acquisitions. Guided by a board of directors with extensive experience in biotechnology and pharmaceutical industries, the company continues to invest in research and development to meet the evolving demands of biologics manufacturing. Repligen’s ongoing focus on quality, scale-up support and single-use technologies positions it as a key supplier in the rapidly growing biologics sector.

Key Stats

• Today's Range: $129.63 to $135.57
• 50-Day Range: $117.54 to $140.92
• 52-Week Range: $102.97 to $182.52
• Volume: 757,950 shs
• Average Volume: 726,303 shs
• Market Capitalization: $7.31 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $170.75
• Consensus Rating: Moderate Buy

Repligen Stock Analysis - MarketRank™

Repligen scored higher than 94% of companies evaluated by MarketBeat, and ranked 68th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Repligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Repligen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 37.21%

Earnings Growth

Earnings for Repligen are expected to grow by 37.21% in the coming year, from $1.72 to $2.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Repligen is -289.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Repligen is -289.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Repligen has a PEG Ratio of 3.84. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Repligen has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.10% of the float of Repligen has been sold short.

Short Interest Ratio / Days to Cover

Repligen has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Repligen has recently increased by 11.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Repligen does not currently pay a dividend.

Dividend Growth

Repligen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.33

Percentage of Shares Shorted

7.10% of the float of Repligen has been sold short.

Short Interest Ratio / Days to Cover

Repligen has a short interest ratio ("days to cover") of 4.7.

Change versus previous month

Short interest in Repligen has recently increased by 11.21%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.97

News Sentiment

Repligen has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Repligen this week, compared to 9 articles on an average week.

Search Interest

2 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Repligen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Repligen is held by insiders.

Percentage Held by Institutions

97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RGEN Stock Analysis - Frequently Asked Questions

How have RGEN shares performed this year?

Repligen's stock was trading at $143.94 at the start of the year. Since then, RGEN stock has decreased by 9.6% and is now trading at $130.19.

How were Repligen's earnings last quarter?

Repligen Corporation (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, April, 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen's revenue for the quarter was up 10.4% on a year-over-year basis.
Read the conference call transcript.

Does Repligen have any subsidiaries?

Repligen subsidiaries include ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and others.

Who are Repligen's major shareholders?

Repligen's top institutional investors include Zevenbergen Capital Investments LLC (0.15%), Krilogy Financial LLC (0.04%), Wealth Enhancement Advisory Services LLC (0.01%) and Trust Point Inc.. Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus and Margaret Pax.
View institutional ownership trends.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Humana (HUM), Meta Platforms (META), Salesforce (CRM), CrowdStrike (CRWD), Broadcom (AVGO) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RGEN
• CIK: 730272
• Web: www.repligen.com
• Phone: (781) 250-0111
• Fax: 781-250-0115
• Employees: 1,778
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Repligen: $170.75
• High Price Target: $200.00
• Low Price Target: $130.00
• Potential Upside/Downside: +31.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 75.69
• P/E Growth: 3.84
• Net Income: -$25.51 million
• Net Margins: -3.93%
• Pretax Margin: -3.53%
• Return on Equity: 4.53%
• Return on Assets: 3.17%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 6.79
• Quick Ratio: 5.79

Sales & Book Value

• Annual Sales: $634.44 million
• Price / Sales: 11.53
• Cash Flow: $3.02 per share
• Price / Cash Flow: 43.13
• Book Value: $35.21 per share
• Price / Book: 3.70

Miscellaneous

• Outstanding Shares: 56,180,000
• Free Float: 55,509,000
• Market Cap: $7.31 billion
• Optionable: Optionable
• Beta: 1.11